http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Sep 2026 09:07:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Press+Releases/Legend+Biotech+to+Participate+in+the+Morgan+Stanley+Global+Healthcare+Conference/27008987.html <p align="justify">BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET.</p> <p align="justify">The live webcast will be available to investors and other interested parties by accessing the <a href="https://www.globenewswire.com/Tracker?data=8y4ku1A1XebS5WUDXZsUS82nl8stzUXwmOMzSru5ZMNck6jbt_R-WItwVWNCR_jQH1gVfpg4carzGBelSSaed7vudsyCfes63r3JyFXkAxc=" rel="nofollow" target="_blank">Investor Relations</a> section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast.</p> http://www.streetinsider.com/Press+Releases/Legend+Biotech+to+Participate+in+the+Morgan+Stanley+Global+Healthcare+Conference/27008987.html Tue, 01 Sep 2026 08:00:00 -0400 LEGN http://www.streetinsider.com/Globe+Newswire/Legend+Biotech+to+Participate+in+the+Morgan+Stanley+Global+Healthcare+Conference/27008987.html <p align="justify">BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET.</p> <p align="justify">The live webcast will be available to investors and other interested parties by accessing the <a href="https://www.globenewswire.com/Tracker?data=8y4ku1A1XebS5WUDXZsUS82nl8stzUXwmOMzSru5ZMNck6jbt_R-WItwVWNCR_jQH1gVfpg4carzGBelSSaed7vudsyCfes63r3JyFXkAxc=" rel="nofollow" target="_blank">Investor Relations</a> section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast.</p> http://www.streetinsider.com/Globe+Newswire/Legend+Biotech+to+Participate+in+the+Morgan+Stanley+Global+Healthcare+Conference/27008987.html Tue, 01 Sep 2026 08:00:00 -0400 LEGN http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS